Roberto Cuttano
Overview
Explore the profile of Roberto Cuttano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cuttano R, Mazzarelli F, Afanga K, Bianchi F, Dama E
J Transl Med
. 2024 Jul;
22(1):632.
PMID: 38972997
Lung cancer is the deadliest cancer type worldwide with ~ 1.8 million deaths per-year. Smoking accounts for ~ 85% of all cases, with a described joint effect with unhealthy diet...
2.
Melocchi V, Cuttano R, Murgo E, Mazzoccoli G, Bianchi F
Cancer Gene Ther
. 2023 Jul;
30(10):1323-1329.
PMID: 37479798
Increasing evidence imputes cancer progression and resistance to therapy to intra-tumor molecular heterogeneity set off by cancer cell plasticity. Re-activation of developmental programs strictly linked to epithelial-to-mesenchymal transition and gaining...
3.
Quarato C, Dama E, Maggi M, Feragalli B, Borelli C, Del Colle A, et al.
Front Med (Lausanne)
. 2023 Jun;
10:1146807.
PMID: 37261121
Objectives: We validated a screening protocol in which thoracic ultrasound (TUS) acts as a first-line complementary imaging technique in selecting patients which may deserve a second-line low-dose high resolution computed...
4.
Cuttano R, Colangelo T, Guarize J, Dama E, Cocomazzi M, Mazzarelli F, et al.
J Hematol Oncol
. 2022 Dec;
15(1):178.
PMID: 36587234
Locally advanced non-small cell lung cancer (NSCLC) is frequent at diagnosis and requires multimodal treatment approaches. Neoadjuvant chemotherapy (NACT) followed by surgery is the treatment of choice for operable locally...
5.
Colangelo T, Panelli P, Mazzarelli F, Tamiro F, Melocchi V, De Santis E, et al.
Mol Cancer
. 2022 Dec;
21(1):226.
PMID: 36550553
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive T-cell malignancy characterized by genotypically-defined and phenotypically divergent cell populations, governed by adaptive landscapes. Clonal expansions are associated to genetic and epigenetic...
6.
MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going
Cuttano R, Afanga M, Bianchi F
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497213
Lung cancer is the leading cause of cancer-related mortality in the world. The development of drug resistance represents a major challenge for the clinical management of patients. In the last...
7.
Colangelo T, Carbone A, Mazzarelli F, Cuttano R, Dama E, Nittoli T, et al.
Cell Death Differ
. 2022 Jan;
29(8):1552-1568.
PMID: 35034102
The circadian gene Timeless (TIM) provides a molecular bridge between circadian and cell cycle/DNA replication regulatory systems and has been recently involved in human cancer development and progression. However, its...
8.
Melocchi V, Dama E, Mazzarelli F, Cuttano R, Colangelo T, Di Candia L, et al.
Oncogene
. 2021 Jun;
40(31):4980-4991.
PMID: 34172935
Lung adenocarcinoma (LUAD) is the main non-small-cell lung cancer diagnosed in ~40-50% of all lung cancer cases. Despite the improvements in early detection and personalized medicine, even a sizable fraction...
9.
Dama E, Melocchi V, Mazzarelli F, Colangelo T, Cuttano R, Di Candia L, et al.
Noncoding RNA
. 2020 Dec;
6(4).
PMID: 33333738
Lung cancer burden can be reduced by adopting primary and secondary prevention strategies such as anti-smoking campaigns and low-dose CT screening for high risk subjects (aged >50 and smokers >30...
10.
Dama E, Melocchi V, Colangelo T, Cuttano R, Bianchi F
J Clin Med
. 2019 Jan;
8(1).
PMID: 30658453
Recent advances in radiological imaging and genomic analysis are profoundly changing the way to manage lung cancer patients. Screening programs which couple lung cancer risk prediction models and low-dose computed...